Ivyland, Pennsylvania – 14 March, 2016 – Ashfield Pharmacovigilance has announced that Colleen Dempsey has joined the company as executive vice president, Medical Information & Pharmacovigilance
Colleen will split her time at Ashfield’s national headquarters in Ivyland, Pennsylvania as well as Ashfield Pharmacovigilance’s office in Research Triangle Park, North Carolina. Colleen comes to Ashfield with 17 years of pharmaceutical experience in research and development with increasing roles of responsibilities. Prior to joining Ashfield, Colleen served as global vice president, Pharmacovigilance quality and operations at Shire Pharmaceuticals. Colleen has strong knowledge of global regulations especially US, EU and Japan and experience with pharmacovigilance systems including data migrations.
Colleen will report to Mary Anne Greenberg, President of Ashfield Medical Information and Pharmacovigilance. Mary Anne said: “We are excited to have Colleen Dempsey join our Medical Information and Pharmacovigilance businesses. Colleen is a thought leader in these fields and brings with her a fresh perspective that will take our expertise to new heights.”
About her appointment, Colleen Dempsey notes: “While at Shire, I led the process to outsource pharmacovigilance work, so I am familiar with the advantages it provides to companies. As I begin this role, I already see the level of talent and quality of work Ashfield provides to clients, so I am excited to use my pharmaceutical industry leadership experience to support the growth in the Pharmacovigilance and Medical Information businesses.”
Colleen joined Shire in 2006 as director, quality, standards and training and held roles in increasing responsibility, including vice president, R&D quality assurance and compliance. While at Shire, Colleen led strategic direction where she oversaw the development of all processes and systems, with a focus on pharmacovigilance in particular, as well as recruited, managed and developed a quality and operational team of 20 professionals. In addition, Colleen was the recipient of the Shire CEO award for her contribution in a divestiture that improved Shire’s financial position.
Prior to Shire, Colleen spent eight years at Wyeth Pharmaceuticals where she served as the director of pharmacovigilance operations. Earlier in her career, Colleen spent 10 years as an RN, working in oncology and cardiology including bedside nursing and clinical research. While working as an RN in clinical research, Colleen played an integral role in editing manuscripts for industry journal articles and has been credited in multiple publications. Colleen graduated with a BSN from Villanova university.